- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Consolidated financial results reveal a revenue growth of 12% to ₹350 crore, driven by increased demand and market expansion. Net profit stands at ₹45 crore, marking a year-over-year decrease of 5%, with Earnings Per Share (EPS) at ₹1.95, affected by higher operational costs, particularly linked to product recalls and quality control measures. Operational costs have risen by 15%, indicating challenges in cost management due to the aforementioned product recalls and temporary manufacturing suspensions.
The balance sheet remains healthy with adequate liquidity, while the cash flow statement shows a stable operational cash flow, suggesting the company can manage working capital effectively despite recent challenges. Strategic focus appears on enhancing quality controls and streamlining operations to mitigate recent setbacks. Given the strong revenue growth coupled with ongoing operational adjustments, maintaining a hold position may be prudent as the company navigates these transitional dynamics.
All announcements from Sanofi Consumer Healthcare India Limited